CD86 and cancer: T-DXd, but not trastuzumab, enhanced CD86 and HLA-DR expression in TDDCs in the coculture setting of NCI-N87 cells and TDDCs, indicating an indirect immunomodulatory effect of T-DXd on DC functionality through cancer cells (Fig. 6D).